|1.||Primary Myelofibrosis (Myelosclerosis)
|5.||Myelodysplastic Syndromes (Myelodysplastic Syndrome)
|1.||Verstovsek, Srdan: 80 articles (11/2015 - 05/2006)|
|2.||Tefferi, Ayalew: 79 articles (12/2015 - 03/2002)|
|3.||Mesa, Ruben A: 58 articles (11/2015 - 03/2002)|
|4.||Barosi, Giovanni: 43 articles (12/2015 - 12/2002)|
|5.||Vannucchi, Alessandro M: 40 articles (11/2015 - 06/2004)|
|6.||Tefferi, A: 32 articles (11/2015 - 01/2000)|
|7.||Hoffman, Ronald: 31 articles (09/2015 - 05/2005)|
|8.||Kröger, Nicolaus: 27 articles (12/2015 - 12/2002)|
|9.||Cervantes, Francisco: 26 articles (11/2015 - 11/2004)|
|10.||Pardanani, Animesh: 26 articles (09/2015 - 05/2002)|
01/01/2015 - "This post hoc analysis evaluated the safety and efficacy of concomitant ruxolitinib and ESA administration in patients enrolled in COMFORT-II, an open-label, phase 3 study comparing the efficacy and safety of ruxolitinib with best available therapy for treatment of myelofibrosis. "
12/01/2013 - "Clinical trials have demonstrated that Ruxolitinib has good therapeutic efficacy for the treatment of myelofibrosis and is currently FDA approved for the treatment of advanced stages of this disease. "
01/01/2015 - "Primary myelofibrosis associated glomerulopathy: significant improvement after therapy with ruxolitinib."
03/01/2012 - "Patients in the ruxolitinib group had an improvement in overall quality-of-life measures and a reduction in symptoms associated with myelofibrosis. "
11/01/2011 - "The authors evaluated the usefulness of serial administration of the Myelofibrosis Symptom Assessment Form as an instrument for the assessment of symptomatic burden and improvement in conjunction with the therapeutic clinical trial of the open label phase 2 trial of the JAK1 and JAK2 inhibitor INCB018424 in patients with MF. "
|2.||Thalidomide (Thalomid)FDA Link
01/01/2015 - "The patient was getting thalidomide for underlying myelofibrosis. "
02/01/2014 - "Here, we report a patient with primary myelofibrosis with leukemic transformation who survived for more than 6 years with thalidomide monotherapy. "
10/01/2009 - "[Advances in thalidomide therapy for idiopathic myelofibrosis]."
07/01/2008 - "Low-dose thalidomide in myelofibrosis."
02/01/2007 - "Mini-dose of thalidomide for treatment of primary myelofibrosis. "
|3.||lenalidomide (CC 5013)FDA Link
04/01/2013 - "Current literature provides conflicting evidence regarding the efficacy of lenalidomide in patients with myelofibrosis (MF). "
10/01/2015 - "The purpose of the present study was to determine whether genes involved in the organization of the hematopoietic niche were dysregulated in patients with primary myelofibrosis (MF) treated with lenalidomide. "
04/01/2013 - "Experience with lenalidomide in an Austrian non-study population with advanced myelofibrosis."
10/01/2015 - "Genes Involved in Maintaining the Bone Marrow Stroma Are Dysregulated in Patients with Myelofibrosis: Lenalidomide Treatment Up-regulates SOCS3."
03/01/2013 - "[Effectiveness and safety of lenalidomide in myelofibrosis patients: a case series from the Spanish compassionate use program]."
|4.||imatinib (Gleevec)FDA Link
05/20/2008 - "Nevertheless, imatinib mesylate induced rapid and complete hematological responses in treated FIP1L1-PDGFRalpha cases, followed by molecular remission and reversal of myelofibrosis. "
11/01/2002 - "We present a CML patient in megakaryoblastic crisis with severe myelofibrosis, who was treated with imatinib at a dosage of 400 mg/day and achieved complete remission together with a marked regression of myelofibrosis after 1 month. "
08/15/2005 - "The current study evaluated the significance of the degree of pretreatment myelofibrosis on response and survival with imatinib therapy in patients with newly diagnosed CML. "
04/01/2008 - "We present a case of Philadelphia positive chronic idiopathic myelofibrosis that had no obvious response to imatinib."
06/01/2007 - "[Reappearance of t(12;17)-positive primary myelofibrosis following Ph+ CML cell reduction by imatinib]."
09/01/2015 - "Hyperactive Janus associated kinase-signal transducers and activators of transcription (JAK-STAT) signaling has been shown to be integral to the pathogenesis of myelofibrosis (MF) regardless of the driver mutational status (JAK2V617F, JAK2 exon 12, MPL515L/K, CALR). "
09/01/2015 - "Selective Janus associated kinase 1 inhibition as a therapeutic target in myelofibrosis."
08/01/2015 - "Myelofibrosis (MF) is a myeloid disorder caused by a clonal hematopoietic stem-cell proliferation associated with activation of the Janus kinase (JAK) signal transducer and activator of transcription (STAT) signaling pathways. "
05/01/2015 - "Although these 3 entities share many pathogenic characteristics, such as dysregulated Janus kinase (JAK)/signal transducer and activator of transcription signaling, they differ substantially regarding prognosis, progression to myelofibrosis (MF), risk of leukemic transformation, and specific medical needs. "
01/01/2015 - "Myelofibrosis (MF) is a clonal haematological disease associated with recurrent somatic gene mutations (JAK2V617F, MPL, CALR) and constitutive activation of the Janus kinase (JAK)/Signal Transducer and Activator of Transcription pathway. "
|6.||Prednisone (Sone)FDA LinkGeneric
10/01/2004 - "We describe the first case of PCH presented as a late manifestation of advanced myelofibrosis associated with antiphospholipid syndrome, that promptly responded to high dosage of prednisone."
01/01/1960 - "Fatal miliary coccidioidomycosis complicating prolonged prednisone therapy in a patient with myelofibrosis."
10/01/2009 - "To investigate the safety and efficacy of the combination of lenalidomide and prednisone in patients with myelofibrosis (MF). "
01/01/2012 - "Ninety-four Mayo Clinic patients with myelofibrosis (MF) participated in two consecutive clinical trials of pomalidomide (0.5-3.5 mg/day), with or without prednisone. "
11/25/2010 - "A multicenter Eastern Cooperative Group (ECOG) phase 2 trial assessed whether adding prednisone to lenalidomide would improve previously reported responses in persons with myelofibrosis (MF). "
10/23/1993 - "The good results obtained with interferon in other chronic myeloproliferative syndromes have led their being tested in idiopathic myelofibrosis, but to date the experience is scarce. "
01/01/1997 - "Recent reports of cytogenetic remission and reversal of bone marrow fibrosis after interferon therapy are of interest. "
10/01/2015 - "Recent studies also suggest a role for recombinant interferon-α in the treatment of 'early stage' primary myelofibrosis, but few studies have reported the bone marrow changes after clinically successful interferon therapy. "
09/01/2013 - "Efficacy and safety of pegylated-interferon α-2a in myelofibrosis: a study by the FIM and GEM French cooperative groups."
10/01/2014 - "We describe a case of pegylated interferon-induced reversible bone marrow aplasia in a patient with primary myelofibrosis. "
|8.||Hydroxyurea (Hydrea)FDA LinkGeneric
01/01/1990 - "We found a significant reduction of bone marrow fibrosis, believed to be mediated by suppression of thrombopoiesis by hydroxyurea."
12/01/2010 - "Hydroxyurea (HU) is frequently given as treatment for myelofibrosis (MF), but data on its efficacy and tolerability are scarce. "
12/01/2010 - "Efficacy and tolerability of hydroxyurea in the treatment of the hyperproliferative manifestations of myelofibrosis: results in 40 patients."
11/01/2003 - "We describe a 63-yr-old patient diagnosed with chronic idiopathic myelofibrosis whose disease was treated with hydroxyurea for 2 yr. He developed respiratory symptoms that were extensively investigated including lung biopsy. "
07/01/2000 - "In contrast, a considerable number of patients displayed a regression of myelofibrosis after hydroxyurea treatment. "
12/01/2000 - "Detection of both increased CD68-positive histiocytes by immunohistochemistry and iron-stained phagocytic cells in marrow biopsy specimens appeared to be helpful for diagnosis of HPS in this patient, whose marrow showed myelofibrosis with hypocellularity."
12/01/1989 - "The iron kinetic model described by Ricketts et al was used to study haemopoiesis in chronic myelofibrosis. "
04/01/2004 - "Moreover, besides myelofibrosis in a number of patients the interstitial compartment displays a remarkable inflammatory reaction with lymphoid nodules, abundant iron-laden macrophages, perivascular plasmacytosis and increase in microvessels. "
05/01/1998 - "To verify whether DFO influences proliferation of erythropoietic precursors, we studied 10 patients on chronic haemodialysis, free from malignancies or other haematological diseases, iron deficiency, bone marrow fibrosis, and Al toxicity. "
07/01/1996 - "Iron deficiency and mild myelofibrosis were found in one patient each. "
|10.||Cytarabine (Cytosar-U)FDA LinkGeneric
10/01/1984 - "Low dose cytosine arabinoside used to induce remission in acute myelofibrosis."
06/01/1994 - "Successful treatment of low dose cytosine arabinoside for acute myelofibrosis with immature myeloblast (AML-MO)"
11/01/1992 - "A 31-year-old man with primary myelofibrosis initially received low dose Ara C. "
06/01/1988 - "[Megakaryoblastic leukemia (acute myelofibrosis): complete remission of a case with low-dose cytosine arabinoside]."
05/01/2003 - "Successful treatment with intermediate dose cytosine arabinoside for myelodysplastic syndrome with acute myelofibrosis."
08/01/2011 - "All 4 JAK2 V617F mutant positive patients achieved molecular remission after a median of 90 days post-transplant, and the median time to regression of bone marrow fibrosis was 180 days."
07/01/2002 - "Nine patients (seven with AML/MDS, two with myelofibrosis) died of transplant-related complications, and 16 are surviving, 14 of them in continuous unmaintained remission. "
02/01/2000 - "We believe that this is the first report to provide clear evidence for the efficacy of DLI in this setting, which also provides evidence for the existence of a T-cell-mediated 'graft vs. myelofibrosis' effect similar to that seen against other haematological malignancies."
04/01/2015 - "In myelofibrosis, stem cell transplant is the current treatment of choice for genetically or clinically high-risk disease; for all other patients requiring treatment, participation in clinical trials may be preferred because currently available drugs, including JAK inhibitors, are palliative and not shown to be disease modifying. "
10/01/2012 - "The aim of this study was to assess disease-specific and transplant-related risk factors that influence post-transplant outcome in patients with myelofibrosis. "
|2.||Stem Cell Transplantation
06/13/2013 - "Allogeneic stem cell transplantation is the only therapeutic modality that provides a cure for myelofibrosis patients. "
10/01/2008 - "In this study, we evaluated the outcome of patients with myelofibrosis who underwent allogeneic stem cell transplantation, and the impact of prognostic factors. "
11/01/2007 - "This study shows that allogeneic stem cell transplantation after reduced-intensity conditioning resulted in rapid regression of bone-marrow fibrosis."
12/01/2015 - "Current Challenges in Stem Cell Transplantation in Myelofibrosis."
12/01/2015 - "Treatment for the majority of patients with myelofibrosis is primarily based on symptom control as curative allogeneic stem cell transplantation is typically offered only to younger patients, especially those with poor prognosis disease. "
|3.||Drug Therapy (Chemotherapy)
04/01/2010 - "Although limited by a small number of patients, this study suggests that patients with myelofibrosis and LT may achieve long-term remission after induction chemotherapy and ASCT."
01/01/1991 - "Cytotoxic chemotherapy did not induce remission, and extensive myelofibrosis developed. "
05/01/2013 - "Myelofibrosis: an update on current pharmacotherapy and future directions."
06/01/2011 - "A greater understanding of the pathophysiology of MPNs is needed before we can cure myelofibrosis with drug therapy. "
06/01/2003 - "The few patients with a regression of myelofibrosis usually presented with severe hypoplasia compatible with a myelo-ablative effect by aggressive chemotherapy. "
|4.||Bone Marrow Transplantation (Transplantation, Bone Marrow)
11/01/1992 - "These results demonstrate that bone marrow transplantation is effective for primary myelofibrosis for which there is no otherwise curative therapy."
09/30/1982 - "The method was used to study suppressor activity of a patient who was treated by bone marrow transplantation for myelofibrosis. "
04/01/2013 - "Here, we describe the case of a female infant diagnosed with primary myelofibrosis at the age of 6 months; she underwent successful matched unrelated bone marrow transplantation with complete resolution of disease. "
01/01/2012 - "Poor outcome of myeloablative conditioned allogeneic bone marrow transplantation for myelofibrosis."
09/01/1997 - "Agnogenic myeloid metaplasia is a rare indication for allogeneic bone marrow transplantation (BMT). "
|5.||Transplantation (Transplant Recipients)
11/01/2014 - "To determine whether umbilical cord blood transplantation (UCBT) is an alternative cure for myelofibrosis (MF), we evaluated 35 UCBTs reported to Eurocord. "
08/01/2004 - "Long-term remission of myelofibrosis following nonmyeloablative allogeneic peripheral blood progenitor cell transplantation in older age: the Scripps Clinic experience."
08/01/2011 - "Transplantation for myelofibrosis: time for a randomized trial."
11/01/2010 - "The role of allogeneic SCT in primary myelofibrosis: a British Society for Blood and Marrow Transplantation study."
11/01/2014 - "Unrelated cord blood transplantation for patients with primary or secondary myelofibrosis."